Generic Drug Price Fixing Settlement: $400M Sandoz Deal OK’d Oct 16

A Connecticut federal judge granted preliminary approval on October 16, 2026 to a $400 million settlement between a coalition of states, Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. Law360 reported it the same day. The deal settles the states’ allegations of generic drug price-fixing and market allocation and, in Law360’s words, sets aside “$280 million as restitution.” The local federal docket feed for Connecticut v. Sandoz, Inc., No. 3:20-cv-00802, shows an “Order on Motion for Settlement” (entry #1571) on the same date. We could not read the order itself. MLex carried the news on October 19.

The terms come from the states’ motion, as summarized by Wolters Kluwer’s VitalLaw. Sandoz pays a “Total Settlement Amount of $400 million dollars.” About 70%, or $280 million, is restitution. The remaining 30%, about $120 million, “will be held by the States to be used for payment of any and all attorney fees and costs.” The restitution is split as follows: “approximately $172 million will be allocated to consumers and approximately $100 million will go to state entities (which include state government instrumentalities and municipalities).” Until final approval the money sits in escrow at Huntington Bank. Sandoz also agrees to a ten-year covenant not to engage in unlawful price-fixing, bid-rigging or market allocation for generic drugs. It must also cooperate in the states’ cases against the companies that have not settled.

The settlement is not final. It “now awaits a scheduled fairness hearing to determine whether the approval is to be finalized.” As of October 21, 2026, we have not found that hearing date, an objection deadline or an exclusion deadline in any document we could read.

People who paid for generic drugs between May 2009 and December 2019 are dealing with three separate pots of money. They have different rules and different deadlines.

1. The class settlements (claims open, deadline November 9, 2026). These are the $533 million end-payer settlements in In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724, in the Eastern District of Pennsylvania. Consumers can claim from two of them. “Sandoz paid $275 million and Sun/Taro paid $200 million to settle all consumer and TPP claims in this lawsuit. Heritage paid $10 million and Apotex paid $48 million to settle the TPP claims in this lawsuit.” TPPs are insurers and employer health plans. The class covers purchases “in the United States (except Indiana and Ohio) and in some United States territories” from May 1, 2009 through December 31, 2019. Payment is pro rata: it “will depend on the number of valid claims and the amount of money you spent on the Named Generic Drugs.” No per-person estimate has been published.

2. The states’ earlier settlements (claims open, deadline March 8, 2027). Earlier state settlements with Glenmark, Lannett, Bausch, Apotex, Heritage and Emcure total $96.5 million. Consumers claim from those through the states’ distribution plan, which the Connecticut court preliminarily approved in September 2026. The court-approved notice says the attorneys general “have recovered approximately $ 25-30 million in Consumer Restitution Funds from Settling Defendants and expect additional settlements and payments.” Eligibility depends on where you live now: “Eligibility is based on where you reside when you submit your claim, not where you made your purchases.” Indiana and Ohio are on the states’ list.

3. The new Sandoz states’ settlement (preliminarily approved, no payment yet). This is the $400 million, with about $172 million for consumers. The Connecticut attorney general puts Sandoz’s total payments to state enforcers, counting earlier deals with other states, at “approximately $469 million.” The states’ notice explains the order of events: “Subsequent Settlements will be scheduled for final approval hearings at future dates.” The states’ distribution plan has its own approval hearing set for September 8, 2027, and the notice adds that “Money will not be distributed until the Court holds a hearing.” As of October 21, 2026, nobody has published a date when Sandoz restitution will reach consumers.

Two state details matter. Indiana and Ohio residents are excluded from the class but are part of the states’ Sandoz deal. Washington’s attorney general lists both states among those joining it. Washington and Idaho “were the only states in the coalition to also secure restitution for businesses.” Washington puts its share at more than $12 million, and Connecticut puts its share at $5.1 million.

The states’ case began with a Connecticut investigation in July 2014. It grew into four complaints in Hartford: Nos. 3:16-cv-02056, 3:19-cv-00710 and 3:20-cv-00802, plus a fourth, 3:26-cv-00160, filed this year against Novartis AG. The Sandoz settlement resolves all four as to Sandoz. According to Connecticut’s release, it also settles allegations that Novartis AG, Sandoz AG and Sandoz Group AG took part in the conduct and “fraudulently transferred assets in order to avoid liability.” The case goes on against the companies that have not settled. The third complaint, “to be tried first, focuses on 80 topical generic drugs” and names 26 corporate and 10 individual defendants. The first trial is set for February 2027 in Hartford. All of this is still allegation. The settling and non-settling defendants “deny any wrongdoing,” and Sandoz said in August that “neither settlement contains an admission of wrongdoing by Sandoz US.”

The size of the coalition varies by source. Connecticut and Washington say 43 states and territories signed the Sandoz deal. MLex’s summary says 48 attorneys general, which matches the coalition behind the states’ distribution plan. New York counts its attorney general plus 47 others.

“Why are generic drugs so cheap?” This case is about the opposite claim. The states allege that “In some instances, the coordinated price increases were over 1,000 percent,” and give digoxin, a heart medication, as an example: it “tripled in price.” The settlements pay back alleged overcharges from 2009 to 2019. They say nothing about generic prices in general. Medicare negotiation is a different program. Questions about which brand-name drugs Medicare negotiated, or whether a drug like Eliquis gets cheaper in 2026, fall outside this case. CMS says the program covers only “single source drugs without generic or biosimilar competition,” starting with 10 Part D drugs whose prices took effect January 1, 2026. For Medicare prices, check with Medicare or your Part D plan.